Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes

Journal of Sexual Medicine

Volumn 3, Issue 2, 2006, Pages 253-266

  Zhang, Xin Hua ^a   Filippi, Sandra ^a   Morelli, Annamaria ^a   Vignozzi, Linda ^a   Luconi, Michaela ^a   Donati, Silvia ^a   Forti, Gianni ^a   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Experimental diabetes; Hypogonadism; Sildenafil; Testosterone

Indexed keywords

ACETYLCHOLINE; ALLOXAN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V; SILDENAFIL; STREPTOZOCIN; TESTOSTERONE ENANTATE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; ELECTROSTIMULATION; ENZYME ANALYSIS; ERECTILE DYSFUNCTION; HYPOGONADISM; IN VITRO STUDY; IN VIVO STUDY; MALE; MUSCLE CONTRACTILITY; NERVE POTENTIAL; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

EID: 33645996073     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2006.00207.x     Document Type: Article

References (59)

1. Saenz de Tejada I, Angulo J, Cellek S, Gonzales-Cadavid N, Heaton J, Pickard R, Simonsen U. Pathophysiology of erectile dysfunction. J Sex Med 2005; 2: 26-39.
2. Close CF, Ryder RE. Impotence in diabetes mellitus. Diabetes Metab Rev 1995; 11: 279-85.
3. Klein R, Klein BE, Lee KE, Moss SE, Cruickshanks KJ. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 1996; 19: 135-41.
4. Corona G, Mannucci E, Mansani R, Petrone L, Bartolini M, Giommi R, Forti G, Maggi M. Organic, relational and psychological factors in erectile dysfunction in men with diabetes mellitus. Eur Urol 2004; 46: 222-8.
5. Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, Chiarini V, Giommi R, Forti G, Maggi M. Association of hyopogonadism and type 2 diabetes in men attending an outpatient erectile dysfunction clinic. Int J Imp Res 2005 [Epub ahead of print].
6. Fedele D, Bortolotti A, Coscelli C, Santeusanio F, Chatenoud L, Colli E, Lavezzari M, Landoni M, Parazzini F. Erectile dysfunction in type 1 and type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int J Epidemiol 2000; 29: 524-31.
7. Hakim LS, Goldestein I. Diabetic sexual dysfunction. Endocrinol Metab Clin North Am 1996; 25: 379-400.
8. Andersson K-E. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 2003; 170 (suppl): 6-13 (discussion: 13-4).
9. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction: Role of the endothelium in erectile physiology and disease. J Androl 2003; 24 (suppl 6): S17-37.
10. Lin CS, Lin G, Lue TF. Cyclic nucleotide signaling in cavernous smooth muscle. J Sex Med 2005; 2: 478-91.
11. Cellek S, Foxwell NA, Moncada S. Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 2353-62.
12. Chang S, Hypolite JA, Velez M, Changolkar A, Wein AJ, Chacko S, DiSanto ME. Downregulation of cGMP-dependent protein kinase-1 activity in the corpus cavernosum smooth muscle of diabetic rabbits. Am J Physiol Regul Integr Comp Physiol 2004; 287: R950-60.
13. Padma-Nathan H, Christ G, Adaikan G, Becher E, Brock G, Carrier S, Carson C, Corbin J, Francis S, DeBusk R, Eardley I, Hedlund H, Hutter A, Jackson G, Kloner R, Lin S, McVary K, McCullough A, Nehra A, Porst H, Schulman C, Seftel A, Sharlip I, Stief C, Teloken C. Pharmacotherapy for erectile dysfunction. J Sex Med 2004; 1: 128-40.
14. Saenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 2159-64.
15. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil Diabetes Study Group: Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26: 777-83.
16. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999; 281: 421-6.
17. Vickers MA, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2002; 14: 466-71.
18. Costabile RA. Optimizing treatment for diabetes mellitus induced erectile dysfunction. J Urol 2003; 170 (suppl): 35-8 (discussion: 39).
19. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 1987; 36: 523-34.
20. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of Aging: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-31.
21. Betancourt-Albrecht M, Cunningham GR. Hypogonadism and diabetes. Int J Impot Res 2003; 15 (suppl 4): S14-20.
22. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5462-8.
23. Corrales JJ, Burgo RM, Garca-Berrocal B, Almeida M, Alberca I, Gonzalez-Buitrago JM, Orfao A, Miralles JM. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004; 53: 666-72.
24. Shabsigh R. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2005; 2: 785-92.
25. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658-63.
26. Aversa A, Isidori AM, Spera E, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003; 58: 632-8.
27. Vignozzi L, Corona G, Petrone L, Filippi S, Morelli A, Forti G, Maggi M. Testosterone and sexual activity. J Endocrinol Invest 2005; 28 (suppl 3): 39-44.
28. Morelli A, Filippi S, Zhang XH, Luconi M, Vignozzi L, Mancina R, Maggi M. Hormonal regulation of peripheral regulatory mechanisms in erection. Int J Androl 2005; 28 (suppl 2): 23-7.
29. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004; 145: 2253-63.
30. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M, Vannelli GB, Mancina R, Forti G, Maggi M. Testosterone regulates PDE5 expression and "in vivo" responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005; 47: 409-16.
31. Miranda FJ, Alabadi JA, Llorens S, Ruiz de Apodaca RF, Centeno JM, Alborch E. Influence of experimental diabetes on regulatory mechanisms of vascular response of rabbit carotid artery to acetylcholine. Life Sci 2000; 66: 2071-80.
32. Ayan S, Sarioglu Y, Yildirim S, Gokce G, Bagcivan I. Relaxation induced by omeprazole does not change in diabetic rabbit corpus cavernosum. BJU Int 2001; 87: 265-8.
33. Filippi S, Marini M, Vannelli GB, Crescioli C, Granchi S, Vignozzi L, Luconi M, Ferruzzi P, Morelli A, Forti G, Ledda F, Maggi M. Effects of hypoxia on endothelin-1 sensitivity in the corpus cavernosum. Mol Hum Reprod 2003; 9: 765-74.
34. Filippi S, Crescioli C, Vannelli GB, Fazzini A, Natali A, Riffaud JP, Maggi M, Ledda F. Effects of NCX 4050, a new NO donor, in rabbit and human corpus cavernosum. Int J Androl 2003; 26: 101-8.
35. Abdelbaky T, Brock GB, Huynh H. Improvement of erectile function in diabetic rats by insulin: Possible role of the insulin-like growth factor system. Endocrinology 1998; 139: 3143-7.
36. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, Wright PA. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999; 29: 297-310.
37. Zhang XH, Filippi S, Vignozzi L, Morelli A, Mancina R, Luconi M, Donati S, Marini M, Vannelli GB, Forti G, Maggi M. Identification, localization and functional "in vitro" and "in vivo" activity of oxytocin receptor in the rat penis. J Endocrinol 2005; 184: 567-76.
38. De Lean A, Munson PJ, Rodbard D. Simultaneous analysis of families of sigmoidal curves: Application to biossay, radioligand assay, and physiological dose-response curves. Am J Physiol 1978; 235: E97-102.
39. Vernet D, Cai L, Garban H, Babbitt ML, Murray FT, Rajfer J, Gonzalez-Cadavid NF. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995; 136: 5709-17.
40. Tanaka T, Nagatani S, Bucholtz DC, Ohkura S, Tsukamura H, Maeda K, Foster DL. Central action of insulin regulates pulsatile luteinizing hormone secretion in the diabetic sheep model. Biol Reprod 2000; 62: 1256-61.
41. Tanaka M, Nakaya S, Kumai T, Watanabe M, Matsumoto N, Kobayashi S. Impaired testicular function in rats with diet-induced hypercholesterolemia and/or streptozotocin-induced diabetes mellitus. Endocr Res 2001; 27: 109-17.
42. Melman A. Pathophysiologic basis of erectile dysfunction. What can we learn from animal models? Int J Impot Res 2001; 13: 140-2.
43. Dorfman VB, Lopez-Costa JJ, Vega C, Bayona JC, Capani F, Fabian Loidl C, Coirini H. Changes of NADPH-diaphorase reactivity in lumbar spinal cord of short-term streptozotocin induced diabetic rats. Brain Res 2004; 997: 185-93.
44. Ballester J, Munoz MC, Dominguez J, Rigau T, Guinovart JJ, Rodriguez-Gil JE. Insulin-dependent diabetes affects testicular function by FSH- and LH-linked mechanisms. J Androl 2004; 25: 706-19.
45. Traish A, Kim N. The physiological role of androgen in penile erection: Regulation of corpus cavernosum structure and function. J Sex Med 2005; 2: 759-70.
46. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: Results of a meta-analysis. Clin Endocrinol 2005; 63: 381-94.
47. Keegan A, Cotter MA, Cameron NE. Corpus cavernosum dysfunction in diabetic rats: Effects of combined alpha-lipoic acid and gamma-linolenic acid treatment. Diabetes Metab Res Rev 2001; 17: 380-6.
48. Nangle MR, Cotter MA, Cameron NE. Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: Relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes 2003; 52: 2396-402.
49. Bivalacqua TJ, Usta MF, Champion HC, Adams D, Namara DB, Abdel-Mageed AB, Kadowitz PJ, Hellstrom WJ. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 2003; 169: 1911-7.
50. Bivalacqua TJ, Champion HC, Usta MF, Cellek S, Chitaley K, Webb RC, Lewis RL, Mills TM, Hellstrom WJ, Kadowitz PJ. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2004; 101: 9121-6.
51. Bennett NE, Kim JH, Wolfe DP, Sasaki K, Yoshimura N, Goins WF, Huang S, Nelson JB, de Groat WC, Glorioso JC, Chancellor MB. Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats. J Urol 2005; 173: 1820-4.
52. Mantelli L, Amerini S, Ledda F, Forti G, Maggi M. The potent relaxant effect of adenosine in rabbit corpora cavernosa is nitric oxide independent and mediated by A2 receptors. J Androl 1995; 16: 312-7.
53. Filippi S, Amerini S, Maggi M, Natali A, Ledda F. Studies on the mechanisms involved in the ATP-induced relaxation in human and rabbit corpus cavernosum. J Urol 1999; 161: 326-31.
54. El-Sakka AI, Lin CS, Chui RM, Dahiya R, Lue TF. Effects of diabetes on nitric oxide synthase and growth factor genes and protein expression in an animal model. Int J Impot Res 1999; 11: 123-32.
55. Escrig A, Marin R, Abreu P, Gonzalez-Mora JL, Mas M. Changes in mating behavior, erectile function, and nitric oxide levels in penile corpora cavernosa in streptozotocin-diabetic rats. Biol Reprod 2002; 66: 185-9.
56. Angulo J, Cuevas P, Fernandez A, Gabancho S, Allona A, Martin-Morales A, Moncada I, Videla S, Saenz de Tejada I. Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. Biochem Biophys Res Commun 2003; 312: 1202-8.
57. Ballester J, Munoz MC, Dominguez J, Rigau T, Guinovart JJ, Rodriguez-Gil JE. Insulin-dependent diabetes affects testicular function by FSH- and LH-linked mechanisms. J Androl 2004; 25: 706-19.
58. Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, Chiarini V, Giommi R, Forti G, Maggi M. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 2005 [Epub ahead of print].
59. Corona G, Petrone L, Mannucci E, Ricca V, Balercia G, Giommi R, Forti G, Maggi M. The impotent couple: Low desire. Int J Androl 2005; 28 (suppl 2): 46-52.